New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

The US pharmaceutical company Eli Lilly has met with the Department of Enterprise to express concerns about planned changes to the patent law in Europe. The multinational, which employs 3,500 people ...

A daily pill to help people newly diagnosed with type 1 diabetes, or those at risk of developing it, live without the ...

Future trial results investigating the role of ivonescimab in patients ... advisory board participation for Eli Lilly, MSD, ...

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

An Alexandria man has been found guilty on seven felony counts including child solicitation and child molesting.

US pharma major Eli Lilly today announced its financial results for the third-quarter of 2025, exceeding expectations and ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...